Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wibmer, C; Amrein, K; Fahrleitner-Pammer, A; Gilg, MM; Berghold, A; Hutterer, GC; Maurer-Ertl, W; Gerger, A; Leithner, A; Pichler, M; Szkandera, J.
Serum sclerostin levels in renal cell carcinoma patients with bone metastases.
Sci Rep. 2016; 6(4):33551-33551
Doi: 10.1038/srep33551
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Wibmer Christine Linda
- Co-Autor*innen der Med Uni Graz
- Amrein Karin
- Berghold Andrea
- Fahrleitner-Pammer Astrid
- Gerger Armin
- Gilg Magdalena Maria
- Hutterer Georg
- Leithner Andreas
- Maurer-Ertl Werner
- Pichler Martin
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker for the use of sclerostin-directed antibodies. As renal cell carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum sclerostin levels in RCC patients. Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with localized disease) and 53 age- and gender-matched non-osteoporotic controls. Frozen serum samples were subjected to sclerostin quantitative sandwich ELISA. The mean serum sclerostin levels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86). Analysis of variance showed no difference between the subgroups of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22). There was no significant association between eGFR (estimated glomerular filtration rate) and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68). Our results indicate that serum sclerostin levels appear not to be a valuable biomarker to assess the occurrence of bone metastases in RCC patients.